Rather, in the setting of thyroid cancer, molecular testing has primarily focused on risk stratification of thyroid nodules,5–7 and testing for somatic mutations in BRAF and TERT is not performed for all patients with a new diagnosis of PTC.4 The current accepted prognostication for PTC has focused on clinical features, including the ATA guidelines for risk stratification, which have been well-validated.4,8,9. The gene discussed is BRAF; the disease is thyroid cancer.